DE3852246D1 - Ethyl-(+)-Apovincaminat zur Behandlung der Demyelinisierung klinischer Erscheinungen autoimmunen Ursprungs. - Google Patents

Ethyl-(+)-Apovincaminat zur Behandlung der Demyelinisierung klinischer Erscheinungen autoimmunen Ursprungs.

Info

Publication number
DE3852246D1
DE3852246D1 DE3852246T DE3852246T DE3852246D1 DE 3852246 D1 DE3852246 D1 DE 3852246D1 DE 3852246 T DE3852246 T DE 3852246T DE 3852246 T DE3852246 T DE 3852246T DE 3852246 D1 DE3852246 D1 DE 3852246D1
Authority
DE
Germany
Prior art keywords
treatment
apovincaminate
ethyl
autoimmune origin
demyelination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3852246T
Other languages
English (en)
Inventor
Gabor Tigyi
Zsuzsa Szegvari
Gryorgy Hajos
Bela Bozoky
Tibor Frank
Laszlo Szporny
Lilla Forgacs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Vegyeszeti Gyar Nyrt
Original Assignee
Richter Gedeon Vegyeszeti Gyar RT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Vegyeszeti Gyar RT filed Critical Richter Gedeon Vegyeszeti Gyar RT
Application granted granted Critical
Publication of DE3852246D1 publication Critical patent/DE3852246D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE3852246T 1987-08-26 1988-08-25 Ethyl-(+)-Apovincaminat zur Behandlung der Demyelinisierung klinischer Erscheinungen autoimmunen Ursprungs. Expired - Lifetime DE3852246D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU873753A HU201674B (en) 1987-08-26 1987-08-26 Process for producing pharmaceutical composition suitable for curing autoimmune-type leukoencephalomyelitic diseases e.g. sclerosis multiplex

Publications (1)

Publication Number Publication Date
DE3852246D1 true DE3852246D1 (de) 1995-01-12

Family

ID=10965341

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3852246T Expired - Lifetime DE3852246D1 (de) 1987-08-26 1988-08-25 Ethyl-(+)-Apovincaminat zur Behandlung der Demyelinisierung klinischer Erscheinungen autoimmunen Ursprungs.

Country Status (6)

Country Link
US (1) US4882336A (de)
EP (1) EP0305181B1 (de)
JP (1) JP2655694B2 (de)
AT (1) ATE114468T1 (de)
DE (1) DE3852246D1 (de)
HU (1) HU201674B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0813411B1 (de) * 1995-02-15 2002-01-23 Takeda Chemical Industries, Ltd. Verwendung von kompocedinderivaten zur inhibierung der bildung oder sekretion von beta-amyloid-protein
US6127387A (en) * 1996-12-10 2000-10-03 Thomas Jefferson University Use of CD4-binding small molecules to inhibit immune responses
US8003094B2 (en) * 2003-06-25 2011-08-23 Charles Erwin Chemical combination and method for increasing delivery of Coenzyme Q10
JP2007521241A (ja) * 2003-10-28 2007-08-02 ウニヴェルシダ ナシオナル アウトノマ デ メヒコ てんかんおよびその併発症の治療および予防のためのビンポセチンおよびその誘導体の使用
RU2262931C2 (ru) * 2003-11-03 2005-10-27 Закрытое Акционерное Общество "Канонфарма Продакшн" Фармацевтическая композиция, обладающая церебровазодилатирующей и ноотропной активностью
CN101888776B (zh) 2007-09-20 2015-03-11 罗切斯特大学 治疗或预防炎性病症的方法和组合物
US20130123208A1 (en) * 2010-05-12 2013-05-16 The Regents of the University of Colorado, a body corporation Method of treating multiple sclerosis with adenosine receptor agonists
US11058637B1 (en) * 2020-11-25 2021-07-13 King Abdulaziz University Surface-modified emulsomes for intranasal delivery of drugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU532001B2 (en) * 1978-11-20 1983-09-15 Sumitomo Chemical Company, Limited Polycyclic indole derivatives

Also Published As

Publication number Publication date
JPS6471814A (en) 1989-03-16
ATE114468T1 (de) 1994-12-15
EP0305181A3 (en) 1990-08-22
HU201674B (en) 1990-12-28
JP2655694B2 (ja) 1997-09-24
EP0305181A2 (de) 1989-03-01
HUT52698A (en) 1990-08-28
US4882336A (en) 1989-11-21
EP0305181B1 (de) 1994-11-30

Similar Documents

Publication Publication Date Title
ES510042A0 (es) "un procedimiento de preparacion de nuevas carboxamidas heterociclicas".
ATE76294T1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
DE59309022D1 (de) Verfahren zur Herstellung von Zahnersatz auf Keramikbasis
DE3856398D1 (de) Verfahren zur Behandlung von Gleitkörpern
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
DE3854004D1 (de) Verfahren zur Herstellung von N-substituiertem Amin.
DE3878627D1 (de) Zusammensetzung zur oberflaechenbehandlung von kautschuk.
DE3788057D1 (de) Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
DE69022269D1 (de) Verfahren zur thermischen Behandlung von Silizium.
DE3888056D1 (de) Oxadiazolyl-azabicycloheptane zur Behandlung von seniler Demenz.
DE3852246D1 (de) Ethyl-(+)-Apovincaminat zur Behandlung der Demyelinisierung klinischer Erscheinungen autoimmunen Ursprungs.
DE3869590D1 (de) Mischung zur behandlung von hypercholesterolemie.
FI864246A (fi) N-substituerade 3-piperidin- eller 3-pyridinkarboxylsyror samt deras derivat.
ATE124681T1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE3855580D1 (de) Verfahren zur Herstellung von Polyparaphenylensulfiden
ATE11013T1 (de) Heilmittelzusammensetzungen zur behandlung der haut.
FI900083A (fi) Nya tetralinderivat.
DE3761377D1 (de) Verfahren zur aufarbeitung von 2-merkaptobenzthiazol enthaltenden teeren.
ES2096559T3 (es) Interferon gamma humano, procedimiento para la preparacion de dicho interferon gamma humano, y su uso.
DE3851376D1 (de) Verfahren zur Herstellung von Triphendioxazinverbindungen.
DE3668116D1 (de) Zusammensetzung zur behandlung von infektionen.
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
DE68918449D1 (de) Siliziumverbindungen zur behandlung von knochen.
DE3877199T3 (de) Verfahren zur Behandlung der Kopfhaut.

Legal Events

Date Code Title Description
8332 No legal effect for de